The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2021 | Assessing the predicative value of the pre-treatment TCR repertoire
Afaf Abed, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia, discusses the implications of using the pre-treatment T-Cell receptor (TCR) repertoire as a predictive and prognostic marker in patients with non-small-cell lung cancer (NSCLC). The pre-treatment TCR repertoire has been effective in predicting progression-free survival (PFS) in patients, but there is no significant association between the pre-treatment TCR repertoire and overall survival (OS), which may be due to a small cohort. Dr Abed additionally highlights the significance of the findings in a clinical and biological context. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
